CANTATA: Primary analysis of a global, randomized, placebo (Pbo)-controlled, double-blind trial of telaglenastat (CB-839) + cabozantinib versus Pbo + cabozantinib in advanced/metastatic renal cell carcinoma (mRCC) patients (pts) who progressed on immune checkpoint inhibitor (ICI) or anti-angiogenic therapies.

Nizar M. Tannir,Neeraj Agarwal,Camillo Porta,Nicola Jane Lawrence,Robert J. Motzer,Richard J. Lee,Rohit K. Jain,Nancy B. Davis,Leonard Joseph Appleman,Oscar B. Goodman,Walter M. Stadler,Sunil G. Gandhi,Daniel M. Geynisman,Roberto Iacovelli,Begoña Mellado,Robert A. Figlin,Thomas Powles,Lalith V Akella,Keith Orford,Bernard Escudier

CANTATA: Primary analysis of a global, randomized, placebo (Pbo)-controlled, double-blind trial of telaglenastat (CB-839) + cabozantinib versus Pbo + cabozantinib in advanced/metastatic renal cell carcinoma (mRCC) patients (pts) who progressed on immune checkpoint inhibitor (ICI) or anti-angiogenic therapies.

2021

4501Background: Dysregulated metabolism is a hallmark of RCC, driven by overexpression of glutaminase (GLS), a key enzyme of glutamine metabolism. Telaglenastat (Tela) is an investigational, first-...

Keywords:

Glutamine metabolism
Medicine
Cabozantinib
Placebo
Renal cell carcinoma
anti angiogenic
Glutaminase
double blind
Cancer research
immune checkpoint inhibitors

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations